Products
Acasunlimab Biosimilar Bispecific Antibody (PD-L1 × 4-1BB) for Research
Pre-made Acasunlimab benchmark antibody (Bispecific mAb, anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-007-1mg | 1mg | |
| GMP-Bios-ab-007-10mg | 10mg | |
| GMP-Bios-ab-007-100mg | 100mg | |
| GMP-Bios-ab-007-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Acasunlimab biosimilar, Bispecific mAb, Anti-CD274/PD-L1;TNFRSF9/CD137 Antibod: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 therapeutic antibody |
| INN Name | Acasunlimab |
| Target | PD-L1;CD137 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | Genmab;BioNTech |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Development Tech | na |
About target - CD274
1. Protein Programmed cell death 1 ligand 1
2. Gene CD274
3. Organism Homo sapiens (Human)
Function
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410).
As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410).
Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410).
The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity).
The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
